SEC Form 4 · accession 0000899243-18-018093
EyePoint, Inc. · EYPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David J Mazzo
Director
Period of report
Jun 21, 2018
Accepted (ET)
Jun 26, 2018 · 2:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314102
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $1.95 | Jun 21, 2018 | A | 33,333 | A | Jun 21, 2019 | Jun 21, 2028 | Common Stock | 33,333 | 33,333 | D |
| Deferred Stock UnitsF1,F2 | — | Jun 21, 2018 | A | 8,333 | A | Jun 21, 2019 | — | Common Stock | 8,333 | 8,333 | D |
Explanation of responses
- F1Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").
- F2Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.